Enhancing Exposure Therapy for Snake and Spider Phobias (Snake/Spider)

Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction

This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders.

Study Overview

• Status: Completed
• Conditions: Specific Phobia
• Intervention / Treatment: Behavioral: Exposure Therapy with Retrieval; Behavioral: Exposure Therapy with Compound Extinction; Behavioral: Exposure Therapy with Retrieval and Compound Extinction; Behavioral: Therapist-guided Exposure Therapy

Detailed Description

This study tests whether exposure therapy for fear of snakes or spiders is enhanced by the addition of a brief fear retrieval trial prior to treatment, and the use of compound extinction during treatment. The goal of the study is to determine whether these behavioral techniques enhance the efficacy of exposure therapy, one of the most empirically supported treatments for anxiety disorders. Individuals between the ages of 18-65 with elevated fear of spiders or fear of snakes are randomly assigned to one of four treatment conditions (1) standard exposure therapy, (2) exposure therapy with fear retrieval augmentation, (3) exposure therapy with compound extinction augmentation, and (4) exposure therapy with fear retrieval and compound extinction augmentations. All participants undergo an online prescreen and a face-to-face screening assessment to determine eligibility and baseline (pre-treatment) symptom severity. Participants additionally complete assessments directly after treatment (post-treatment), and approximately one week after treatment (follow-up). The pre-treatment assessment occurs 1-14 days prior to treatment, the post-treatment assessment occurs during the treatment visit as soon as the treatment procedure is complete, and the follow-up assessment occurs within a window of 6-14 days after the completion of treatment. Participants complete two behavioral approach tests (in the treatment context and in the generalization context) at pre-treatment, post-treatment, and follow-up. Participants complete a battery of self-report questionnaires at pre-treatment and follow-up.

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Austin, Texas, United States, 78712
      • University of Texas at Austin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18 to 65.
2. Speaks English fluently.
3. A score of 70 or higher on the Fear of Snakes/Spiders Questionnaire.
4. Demonstrates avoidance during behavioral approach tests (defined as inability to put palm flat on the bottom of a tank containing a snake/spider, and inability to touch a snake/spider with a bare finger).

Exclusion Criteria:

1. Unstable dose of psychotropic medications during the 4 weeks prior to baseline assessment.
2. Currently receiving exposure-based treatment for snake/spider phobia.
3. Currently at risk for suicide.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: FACTORIAL
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Exposure with Retrieval; Exposure Therapy with Retrieval	Behavioral: Exposure Therapy with Retrieval; Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
Experimental: Exposure with Compounding; Exposure Therapy with Compound Extinction	Behavioral: Exposure Therapy with Compound Extinction; Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
Experimental: Exposure with Retrieval and Compounding; Exposure Therapy with Retrieval and Compound Extinction	Behavioral: Exposure Therapy with Retrieval and Compound Extinction; Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
Active Comparator: Therapist-Guided Exposure Therapy; Therapist-guided Exposure Therapy	Behavioral: Therapist-guided Exposure Therapy; Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to follow-up	pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in peak subjective fear (0 - 100), behavioral approach (0 - 4), and heart rate reactivity to a live snake/spider not used during treatment (generalization context) from pre-treatment to post-treatment.		pre-treatment (window of 1-14 days prior to treatment); post-treatment (directly after the treatment procedure is completed)
Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in peak subjective fear (0 - 100), behavioral approach (1 - 8), and heart rate reactivity to a live snake/spider used during treatment (treatment context) from pre-treatment to post-treatment		pre-treatment (window of 1-14 days prior to treatment); post-treatment (directly after the treatment procedure is completed)
Change in Fear of Snakes/Spiders Questionnaire from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in Snake/Spider Belief Questionnaire from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in Agoraphobic Cognitions Questionnaire for Snake/Spider Phobia from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in Self-Efficacy Questionnaire for Spider/Snake Phobia from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in Armfield and Mattiske Disgust Questionnaire from pre-treatment to follow-up		pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)
Change in Lab for the Study of Anxiety Disorders Specific Phobia Diagnostic Questionnaire from pre-treatment to follow-up	change from pre-treatment in current phobic diagnostic status and in level of phobic-related distress and impairment	pre-treatment (window of 1-14 days prior to treatment); follow-up (window of 6-14 days after treatment)

Collaborators and Investigators

• Sponsor: University of Texas at Austin
• Collaborators: National Institute of Mental Health (NIMH)
• Investigators: Principal Investigator: Michael J Telch, PhD, University of Texas at Austin

Publications and helpful links

General Publications

• Lancaster CL, Monfils MH, Telch MJ. Augmenting exposure therapy with pre-extinction fear memory reactivation and deepened extinction: A randomized controlled trial. Behav Res Ther. 2020 Dec;135:103730. doi: 10.1016/j.brat.2020.103730. Epub 2020 Sep 19.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2012
• Primary Completion (Actual): December 1, 2019
• Study Completion (Actual): December 1, 2019

Study Registration Dates

• First Submitted: January 22, 2014
• First Submitted That Met QC Criteria: June 6, 2014
• First Posted (Estimate): June 10, 2014

Study Record Updates

• Last Update Posted (Actual): December 8, 2020
• Last Update Submitted That Met QC Criteria: December 4, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Anxiety Disorders; Phobic Disorders
• Other Study ID Numbers: 2011-10-0012; 1F31MH100760-01 (U.S. NIH Grant/Contract)